Khindri Sanjeev sold $271K of LQDA

Khindri Sanjeev (Chief Development Officer) sold 4,134 shares of Liquidia Corp (LQDA) at $65.46 ($0.27M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khindri Sanjeev
Published Jun 10, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure adds incremental information about insider liquidity/positioning but does not introduce new company fundamentals (no guidance, trial results, or regulatory actions).

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article lacks context on total insider activity, prior sales cadence, and whether the sale was for diversification/tax—so the signal-to-noise is low.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-10; transaction dated 2026-06-08.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp (LQDA) disclosed an insider open-market sale by CDO Khindri Sanjeev: 4,134 shares sold at $65.46 on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive value; the article provides no new operational/clinical/regulatory catalyst.

Market effects

Minimal; single-company insider sale without new sector/regulatory developments.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term risk; traders may use it as a sentiment check rather than a fundamental signal.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Khindri Sanjeev

    Chief Development Officer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.